Company intelligence / Profile preview

Nasaleze

Ownership: Private
Development stage: Other

Overview

The company’s products are clinically proven, drug-free nasal sprays that create a physical barrier in the nose using patented cellulose powder. Clinical studies have demonstrated effectiveness for reducing symptoms of allergic rhinitis and providing protection from airborne pathogens including viruses such as Covid‑19. Products are available over-the-counter in multiple countries under various trade names.

Therapeutic areas: ImmunologyPulmonologyInfectious Diseases
Modalities: Device (nasal spray containing cellulose powder)
Industry: Therapeutic Medical Devices

Partnerships

Clinical Accelerator (for clinical trials management)

Beyond the preview

Go deeper on Nasaleze.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nasaleze.